ArticleMetabolic brain disease2026
Neuroprotective effect of sinomenine on parkinson's disease through NLRP3/Caspase-1/GSDMD pathway-mediated pyroptosis inhibition.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mounting evidence indicates that NLRP3 inflammasome-mediated pyroptosis is critically involved in Parkinson’s disease (PD) pathogenesis. Sinomenine (SN) possesses neuroprotective properties and is known to modulate the NLRP3 inflammasome, but its potential to protect against PD via pyroptosis inhibition remains unexplored. This study demonstrates that SN confers significant neuroprotection in both cellular and animal PD models. Key findings show that SN alleviates motor deficits and nigral pathology in vivo, enhances neuronal viability, and suppresses pyroptosis in vitro. Mechanistically, SN potently inhibits NLRP3 inflammasome activation and subsequent cleavage of Caspase-1 and GSDMD, reducing levels of IL-1β and IL-18. The enhanced protection observed with the NLRP3 inhibitor MCC950 co-treatment validates the involvement of this pathway. Our results establish that SN mitigates PD-associated damage primarily by targeting the NLRP3/Caspase-1/GSDMD-mediated pyroptotic pathway.
Indexed as
Identifiers
41557055What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.